US2024024423A1PendingUtilityA1

Heparin-Associated Polypeptides and Uses Thereof

73
Assignee: JUVENA THERAPEUTICS INCPriority: Jun 27, 2018Filed: Aug 10, 2023Published: Jan 25, 2024
Est. expiryJun 27, 2038(~11.9 yrs left)· nominal 20-yr term from priority
Inventors:Hanadie YousefJeremy O'ConnellThach Mai
A61K 38/2086A61K 9/0019A61P 21/00A61K 38/30A61K 38/1709A61K 38/1825A61K 38/39
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described herein are therapeutic compositions comprising heparin-associated polypeptides useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A fusion protein, comprising:
 a serum albumin protein; and   an insulin-like growth factor 2 (IGF2) protein linked to the serum albumin protein.   
     
     
         2 . The fusion protein of  claim 1 , wherein the serum albumin protein and the IGF2 protein are covalently linked. 
     
     
         3 . The fusion protein of  claim 2 , wherein the serum albumin protein is N-terminal to the covalently linked IGF2 protein. 
     
     
         4 . The fusion protein of  claim 2 , wherein the serum albumin protein is C-terminal to the covalently linked IGF2 protein. 
     
     
         5 . The fusion protein of  claim 2 , wherein the covalently linked serum albumin protein and IGF2 protein are arranged in a single polypeptide in an orientation consistent with an N-terminal to C-terminal orientation of native serum albumin protein and IGF2 protein. 
     
     
         6 . The fusion protein of  claim 1 , wherein the IGF2 protein comprises a product of an IGF2 pro-protein. 
     
     
         7 . The fusion protein of  claim 1 , wherein the IGF2 protein comprises an active domain of an IGF2 pro-protein. 
     
     
         8 . The fusion protein of  claim 1 , comprising a modification to the IGF2 protein. 
     
     
         9 . The fusion protein of  claim 1 , wherein the IGF2 protein comprises a non-naturally occurring IGF2 protein sequence. 
     
     
         10 . The fusion protein of  claim 1 , wherein the fusion protein associates with a polypeptide comprising a heparin-binding domain. 
     
     
         11 . The fusion protein of  claim 1 , wherein the serum albumin protein is a human serum albumin polypeptide. 
     
     
         12 . The fusion protein of  claim 1 , wherein the serum albumin protein and the IGF2 protein are linked by a peptide linker. 
     
     
         13 . A pharmaceutical composition comprising:
 a serum albumin protein;   an insulin-like growth factor 2 (IGF2) protein linked to the serum albumin protein; and   a pharmaceutically acceptable excipient, carrier, or diluent.   
     
     
         14 . The pharmaceutical composition of  claim 13 , wherein the serum albumin protein and the IGF2 protein are covalently linked. 
     
     
         15 . The pharmaceutical composition of  claim 14 , wherein the serum albumin protein is N-terminal to the covalently linked IGF2 protein. 
     
     
         16 . The pharmaceutical composition of  claim 13 , wherein the IGF2 protein comprises a product of an IGF2 pro-protein. 
     
     
         17 . The pharmaceutical composition of  claim 13 , wherein the IGF2 protein comprises an active domain of an IGF2 pro-protein. 
     
     
         18 . The pharmaceutical composition of  claim 13 , wherein the IGF2 protein is non-naturally occurring. 
     
     
         19 . The pharmaceutical composition of  claim 18 , wherein the serum albumin protein and the non-naturally occurring IGF2 protein are linked by a peptide linker. 
     
     
         20 . The pharmaceutical composition of  claim 13 , wherein the serum albumin protein is a human serum albumin polypeptide.

Join the waitlist — get patent alerts

Track US2024024423A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.